Created at Source Raw Value Validated value
June 25, 2024, noon usa

* covid-19 patients with critical manifestations. * sepsis. * acute respiratory distress syndrome (ards). * decompensated liver disease (child-pugh class b or c disease). * chronic renal impairment. * patients with blood diseases (severe anemia, thalassemia, itp, leukemia ....). * ischemic heart disease within the last 6 months. * chronic pulmonary disease. * malignancy. * pregnancy or breastfeeding. * hypersensitivity to sofosbuvir or ribavirin. * patients with organ transplant. * unwilling to participate in our study

* covid-19 patients with critical manifestations. * sepsis. * acute respiratory distress syndrome (ards). * decompensated liver disease (child-pugh class b or c disease). * chronic renal impairment. * patients with blood diseases (severe anemia, thalassemia, itp, leukemia ....). * ischemic heart disease within the last 6 months. * chronic pulmonary disease. * malignancy. * pregnancy or breastfeeding. * hypersensitivity to sofosbuvir or ribavirin. * patients with organ transplant. * unwilling to participate in our study

Oct. 26, 2020, 11:31 p.m. usa

- covid-19 patients with critical manifestations. - sepsis. - acute respiratory distress syndrome (ards). - decompensated liver disease (child-pugh class b or c disease). - chronic renal impairment. - patients with blood diseases (severe anemia, thalassemia, itp, leukemia ….). - ischemic heart disease within the last 6 months. - chronic pulmonary disease. - malignancy. - pregnancy or breastfeeding. - hypersensitivity to sofosbuvir or ribavirin. - patients with organ transplant. - unwilling to participate in our study

- covid-19 patients with critical manifestations. - sepsis. - acute respiratory distress syndrome (ards). - decompensated liver disease (child-pugh class b or c disease). - chronic renal impairment. - patients with blood diseases (severe anemia, thalassemia, itp, leukemia ….). - ischemic heart disease within the last 6 months. - chronic pulmonary disease. - malignancy. - pregnancy or breastfeeding. - hypersensitivity to sofosbuvir or ribavirin. - patients with organ transplant. - unwilling to participate in our study